1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Gout Therapeutics Market
2.2. Global Gout Therapeutics Market, By Drug Class, 2023 (US$ Million)
2.3. Global Gout Therapeutics Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Gout Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Gout Therapeutics Market Vendors
3.2. Strategies Adopted by Gout Therapeutics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Gout Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Gout Therapeutics Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.3.2. Colchicine
5.3.3. Corticosteroids
5.3.4. Uric Acid Lowering Agents


6. North America Gout Therapeutics Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
6.3.Gout Therapeutics Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)

7. UK and European Union Gout Therapeutics Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
7.3.Gout Therapeutics Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)

8. Asia Pacific Gout Therapeutics Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.3.Gout Therapeutics Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)

9. Latin America Gout Therapeutics Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
9.3.Gout Therapeutics Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)

10. Middle East and Africa Gout Therapeutics Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
10.3.Gout Therapeutics Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Gout Therapeutics Market: By Drug Class, 2022-2032, USD (Million)

11. Company Profile
11.1. Ardea Biosciences, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. AstraZeneca plc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. BioCryst Pharmaceuticals, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Cymabay Therapeutics, Inc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. GlaxoSmithKline plc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Horizon Pharma Plc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Regeneron Pharmaceuticals, Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Sanofi Aventis
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Savient Pharmaceuticals, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Selecta Biosciences, Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Takeda Pharmaceutical Company Ltd.
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Teijin Pharma Ltd.
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives